Other than the CpG adjuvant PD-1/PD-L-1 blockade toll-like receptor activation, inhibiting the expression of indoleamine 2,3-dioxygenase (IDO) is another strategy in cancer immunotherapy. Here, IDO1 is linked to cancer.